Show simple item record

dc.contributor.authorSolomon, B
dc.contributor.authorCappuzzo, F
dc.contributor.authorFelip, E
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorCosta, D
dc.contributor.authorKim, D
dc.contributor.authorNakagawa, K
dc.contributor.authorWu, Y
dc.contributor.authorMekhail, T
dc.contributor.authorPaolini, J
dc.contributor.authorTursi, J
dc.contributor.authorUsari, T
dc.contributor.authorWilner, K
dc.contributor.authorSelaru, P
dc.contributor.authorMok, T
dc.date.accessioned2016-04-18T08:48:11Zen
dc.date.available2016-04-18T08:48:11Zen
dc.date.issued2016-03-28en
dc.identifier.citationIntracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. 2016: J Clin Oncolen
dc.identifier.issn1527-7755en
dc.identifier.pmid27022118en
dc.identifier.doi10.1200/JCO.2015.63.5888en
dc.identifier.urihttp://hdl.handle.net/10541/605645en
dc.description.abstractIntracranial efficacy of first-line crizotinib versus chemotherapy was compared prospectively in the phase III PROFILE 1014 study in ALK-positive non-small-cell lung cancer.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncologyen
dc.titleIntracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014.en
dc.typeArticleen
dc.contributor.departmentBenjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen
dc.identifier.journalJournal of Clinical Oncologyen
html.description.abstractIntracranial efficacy of first-line crizotinib versus chemotherapy was compared prospectively in the phase III PROFILE 1014 study in ALK-positive non-small-cell lung cancer.


This item appears in the following Collection(s)

Show simple item record